|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissue showed significantly higher CDH13 and RASSF1 methylation levels compared with normal lung tissue, but lower LINE-1 methylation levels.
|
20371677 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor size was associated with RIL and CDH13 methylation (both p = 0.002), and S-phase was associated with RIL methylation (p = 0.036).
|
22695491 |
2012 |
|
High Grade Lymphoma (neoplasm)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High-grade lymphomas with diploid DNA histograms tended to express high levels of p105 in all phases of the cell cycle.
|
2569301 |
1989 |
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDH13, which functions in cell-cell adhesion, seems to be involved in liver carcinogenesis.
|
12374686 |
2002 |
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Cadherin-13 (CDH13) is a newly characterized cadherin molecule responsible for selective cell recognition and adhesion, the expression of which is decreased by methylation in a variety of human cancers, indicating that the CDH13 gene functions as a tumor suppressor gene.
|
12697869 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cadherin-13 (CDH13) is a newly characterized cadherin molecule responsible for selective cell recognition and adhesion, the expression of which is decreased by methylation in a variety of human cancers, indicating that the CDH13 gene functions as a tumor suppressor gene.
|
12697869 |
2003 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer.
|
14997203 |
2004 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
CDH13 hypermethylation showed discriminative receiver-operator characteristic curve profiles, sharply demarcating esophageal adenocarcinoma (EAC) from esophageal squamous cell carcinoma (ESCC) and normal esophagus (NE) (p < 0.0001).
|
18729198 |
2008 |
|
Substance Use Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
CDH13 has been implicated previously in substance use disorders.
|
18821565 |
2008 |
|
Malignant neoplasm of ovary
|
0.030 |
Biomarker
|
disease |
BEFREE |
CDH13, GSTP1 and RASSF1 are frequently methylated in both sporadic and BRCA1-associated ovarian cancers.
|
20840667 |
2010 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
CDH13 methylation was found in 39 patients with bladder TCC (30.7%) but in no controls.
|
21672320 |
2011 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
CDH13 methylation was significantly associated with advanced tumour stage, high-grade tumour, large tumour size, tumour recurrence and poor prognosis.
|
21672320 |
2011 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer.
|
21796503 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cadherin 13 (H-cadherin; CDH13) methylation levels were significantly higher in the HER2 tumors compared to the luminal A and basal-like subtypes.
|
23467623 |
2013 |
|
Luminal A Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cadherin 13 (H-cadherin; CDH13) methylation levels were significantly higher in the HER2 tumors compared to the luminal A and basal-like subtypes.
|
23467623 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cadherin 13 overexpression as an important factor related to the absence of tumor fluorescence in 5-aminolevulinic acid-guided resection of glioma.
|
24010971 |
2013 |
|
Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Cadherin 13 overexpression as an important factor related to the absence of tumor fluorescence in 5-aminolevulinic acid-guided resection of glioma.
|
24010971 |
2013 |
|
Hyperactive behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Cadherin-13 gene is associated with hyperactive/impulsive symptoms in attention/deficit hyperactivity disorder.
|
25739828 |
2015 |
|
Impulsive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cadherin-13 gene is associated with hyperactive/impulsive symptoms in attention/deficit hyperactivity disorder.
|
25739828 |
2015 |
|
Impulsive character (finding)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cadherin-13 gene is associated with hyperactive/impulsive symptoms in attention/deficit hyperactivity disorder.
|
25739828 |
2015 |
|
Metabolic Syndrome X
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass.
|
26423718 |
2016 |
|
Endometrial Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
CDH13 and SHP1 promoters were highly methylated (81.36% and 86.44%, respectively) in endometrial carcinoma, while CDH13 promoter methylation was also present in complex hyperplasia and atypical hyperplasia (51.72% and 50.00%, respectively).
|
26597461 |
2016 |
|
Colorectal Carcinoma
|
0.080 |
PosttranslationalModification
|
disease |
BEFREE |
CDH13 promoter methylation had a significantly increased risk for poorly differentiated CRC (OR = 4.07, P = 0.001).
|
28121942 |
2017 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
CDH13 promoter methylation was not associated with sex status, tumor stage, and lymph node status (all P > 0.05).
|
28121942 |
2017 |
|
Ischemic stroke
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CDH13 genetic polymorphisms are associated with adiponectin levels and ischemic stroke.
|
28245897 |
2017 |